Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Loss of Tumor Suppressor Gene Functions01:12

Loss of Tumor Suppressor Gene Functions

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
Loss of Tumor Suppressor Gene Functions01:12

Loss of Tumor Suppressor Gene Functions

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Retracted] Kevetrin induces apoptosis in <i>TP53</i> wild‑type and mutant acute myeloid leukemia cells.

Oncology reports·2026
Same author

Talazoparib engages innate immune activation via PARP trapping-dependent cGAS/STING activation in Ewing Sarcoma.

Cancer letters·2026
Same author

Drug-loaded biomorphic scaffolds for tissue regeneration and targeted antitumor therapy in bone metastasis models.

Biomaterials advances·2026
Same author

Advancing the Science of Surgical Education: Reflections From the 2025 University of Melbourne Department of Surgery Research Showcase.

ANZ journal of surgery·2026
Same author

FOS3D: A Fluorescence-Enabled Toolkit for Characterizing a Three-dimensional Osteosarcoma Model.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same author

Circulating IGF2BP3 enables risk stratification and predicts treatment response in Ewing sarcoma.

Scientific reports·2026

Related Experiment Video

Updated: Jun 15, 2026

The In ovo CAM-assay as a Xenograft Model for Sarcoma
12:44

The In ovo CAM-assay as a Xenograft Model for Sarcoma

Published on: July 17, 2013

25.5K

Modeling Myxofibrosarcoma: Where Do We Stand and What Is Missing?

Enrico Lucarelli1, Alessandro De Vita2, Chiara Bellotti1

  • 1Osteoncology, Bone and Soft Tissue Sarcomas and Innovative Therapies Unit, IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna, Italy.

Cancers
|November 14, 2023
PubMed
Summary

Myxofibrosarcoma (MFS), a soft tissue sarcoma (STS), frequently recurs locally, necessitating better understanding and treatments. This review details available MFS models to aid future research and therapeutic development.

Keywords:
cell linesdisease modelsin vitroin vivo and ex vivo modelsmusculoskeletal tissuesmyxofibrosarcomapatient-derived cell linesrare tumorssarcomasoft-tissue tumorstumor models

More Related Videos

Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells
08:52

Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells

Published on: June 13, 2018

8.9K
A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

9.6K

Related Experiment Videos

Last Updated: Jun 15, 2026

The In ovo CAM-assay as a Xenograft Model for Sarcoma
12:44

The In ovo CAM-assay as a Xenograft Model for Sarcoma

Published on: July 17, 2013

25.5K
Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells
08:52

Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells

Published on: June 13, 2018

8.9K
A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

9.6K

Area of Science:

  • Oncology
  • Sarcoma Research
  • Translational Medicine

Background:

  • Myxofibrosarcoma (MFS) is a malignant soft tissue sarcoma (STS) characterized by myxoid and fibrous components, primarily affecting older adults.
  • With increasing lifespans, MFS is projected to become a more prevalent musculoskeletal sarcoma.
  • MFS exhibits a high rate of local recurrence, often multiple times, leading to repeated surgeries and potential functional impairment.

Purpose of the Study:

  • To review and describe the currently available preclinical models for Myxofibrosarcoma.
  • To provide insights into the advantages and limitations of each MFS model.
  • To highlight the need for improved MFS models to advance understanding and therapeutic development.

Main Methods:

  • Literature review of existing Myxofibrosarcoma preclinical models.
  • Analysis of the characteristics, utility, and drawbacks of each model.
  • Synthesis of information to guide future model development and selection.

Main Results:

  • Few preclinical models for Myxofibrosarcoma are currently available.
  • Existing models vary in their ability to recapitulate MFS biology, including local recurrence and metastatic potential.
  • The review identifies gaps in current MFS modeling capabilities.

Conclusions:

  • A better understanding of Myxofibrosarcoma biology and improved therapeutic options are urgently needed.
  • Development and utilization of robust preclinical models are crucial for advancing MFS research.
  • Further investigation into the advantages and constraints of existing MFS models will inform the creation of more effective preclinical tools.